Engflag

MomeGalen

Quick links to important sections

MomeGalen

MomeGalen_NB

Method of action: Antiallergic, Anticonvulsant, Antiexudative, Anti-Inflammatory, Antipruritic, Corticosteroids, Dermatological Preparations, Drugs For Obstructive Airway Diseases, Glucocorticoid, Glucocorticoid (Local), Nasal Preparations

Treatment option: Asthma, Atopic Dermatitis, Plaque Psoriasis, Dermatitis, Dermatitis,Atopic, Jock Itch, Nasal Polyps, Psoriasis, Rhinitis, Rhinosinusitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of MomeGalen

What is MomeGalen? An Essential Overview

Property Description
Active ingredient Mometasone Furoate
Form Topical preparations, Nasal spray, Inhaler
Pharmacological class Corticosteroid (Glucocorticoid)
General use Suppressing inflammation and related symptoms
Origin Synthetic compound

MomeGalen is a pharmaceutical product defined by its sole active component, Mometasone Furoate, which is fundamentally classified as a potent synthetic corticosteroid or glucocorticoid. Its primary purpose is to suppress inflammation and irritation in targeted areas, making it effective for general relief from inflammatory symptoms.

Defining MomeGalen: Type and Pharmacological Class

MomeGalen is a synthetic medicinal product derived from prednisolone, belonging to the established pharmacological class of corticosteroids. The active ingredient, Mometasone Furoate, is an engineered molecule designed for potent, targeted action. Mometasone is categorized as a high-potency topical glucocorticoid, with its efficacy recognized for resolving moderate to severe inflammatory symptoms in patient groups, including adults and pediatric patients. This classification confirms its role in modulating the immune response to reduce irritation and swelling.

Composition and Forms for Targeted Use

MomeGalen is consistently presented as a single-ingredient product, containing only Mometasone Furoate alongside specialized excipients that form the base or vehicle. The drug is formulated to maximize local anti-inflammatory activity while minimizing systemic exposure through its furoate ester structure. Due to its versatility, the medicine is available in multiple dosage forms, including topical preparations like cream and ointment for dermal use, an aqueous vehicle for nasal application as a nasal spray, and a dry powder for inhalation.

General Purpose: Suppressing Inflammation and Itching

The general therapeutic purpose of MomeGalen is to utilize its potent anti-inflammatory property to resolve the physical manifestations of swelling, redness, and irritation. By reducing local immune activity, the medication provides an antipruritic (anti-itch) benefit, addressing severe discomfort. This core function is central to its profile, providing foundational relief by directly modifying the underlying inflammatory processes.

Regulatory References

  1. NIH DailyMed Drug Information

What side effects are possible with MomeGalen?

Possible Side Effects and Safety Information

MomeGalen (mometasone furoate) is a topical corticosteroid, and like all medicines, it can cause side effects. These effects are generally mild and localized, but it is important to be aware of all potential risks.

Common Side Effects

The most frequently reported side effects occur at the application site and may include a temporary sensation of burning, stinging, or itching. Other common skin reactions include:

  • Skin atrophy (thinning)
  • Acne or acneiform reactions
  • Folliculitis (inflammation of the hair follicles)
  • Skin discoloration (lightening or darkening)
  • Dryness or irritation

These local effects are more likely with prolonged use or when applied under occlusive dressings.

Less Common and Serious Side Effects

Systemic absorption of the medicine through the skin is uncommon but can occur, especially when applied over large surface areas, for a long duration, or in children. This absorption may lead to serious side effects, which require immediate medical attention:

  • Adrenal gland suppression (Hypothalamic-Pituitary-Adrenal axis suppression), which may present as unusual tiredness, weight loss, or dizziness.
  • Cushing's syndrome (symptoms include a rounded face and weight gain in the upper body).
  • Vision problems such as glaucoma or cataracts.
  • Signs of a new skin infection (e.g., increased redness, swelling, or pus).

Safety Precautions

Do not use MomeGalen if you have a known allergy to mometasone furoate or any other ingredient. This medication is typically not recommended for use on existing skin infections like bacterial, viral (e.g., herpes, chickenpox), or fungal infections, as it may worsen them. Do not use the cream near the eyes. Consult a healthcare professional immediately if you experience any sign of a severe allergic reaction (such as swelling of the face, tongue, or throat) or if your skin condition worsens or does not improve after two weeks of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for MomeGalen (mometasone furoate nasal spray) emphasizes that acute overdose, such as a single event of accidental high dosage, is unlikely to cause severe or life-threatening symptoms due to the medication’s low absorption into the body. This product has a low acute toxicity profile.

However, the primary concern for overdose is the potential for chronic toxicity resulting from the long-term use of doses higher than those recommended by a healthcare professional.

Documented Overdose Effects (Chronic Exposure)

Physiological System Potential Manifestation
Endocrine System Adrenal suppression (HPA axis suppression)
Metabolic System Hypercorticism (Cushingoid features)
Growth Potential for growth reduction (in children/adolescents)

Adrenal Suppression is the most significant documented risk of chronic overdose. If a patient has used higher-than-recommended doses for prolonged periods, they may develop a reduced ability to produce necessary stress hormones. In periods of stress, such as severe illness, trauma, or elective surgery, individuals with adrenal suppression may require additional systemic corticosteroid support.

When Immediate Medical Help is Required

If you suspect an overdose, or if you have been using more than the prescribed dosage for a long time, you must seek medical advice immediately.

It is crucial to contact a healthcare professional if you experience signs or symptoms associated with adrenal insufficiency or withdrawal from systemic steroids, which may include joint and/or muscular pain, profound weakness (lassitude), or depression. Any patient receiving long-term treatment should be periodically monitored by a doctor for potential systemic effects.

Therapeutic Uses of MomeGalen

Quick Facts

Condition
Seasonal allergic rhinitis (hay fever)
Perennial allergic rhinitis (year-round allergies)
Nasal polyps
Inflammation and itching from corticosteroid-responsive skin conditions

MomeGalen is a prescription medication utilized to address a range of inflammatory and allergic conditions. Its main purpose is to support the management of symptoms associated with specific conditions.

In the nasal administration form, MomeGalen is indicated for the management and supportive care of nasal symptoms related to both seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis (year-round allergies). These symptoms typically include sneezing, nasal discharge, and congestion. It is also a treatment option for nasal polyps in adults.

For the topical administration form (cream, ointment, or lotion), the medication is used in the care of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis and atopic dermatitis. Its application in these contexts is intended to provide relief from associated redness and itching, supporting overall skin comfort. For a comprehensive list of approved indications, consult official product labeling or a healthcare professional.

Regulatory References

  1. NIH DailyMed guidance for Mometasone Furoate

Eligibility and Restrictions for Use

Who Can and Cannot Use MomeGalen?

The official eligibility for MomeGalen (Mometasone Furoate) is determined by specific age, physiological status, and contraindication criteria defined by regulatory authorities.

Absolute Contraindications

MomeGalen is strictly contraindicated and must not be used in:

  • Patients with documented hypersensitivity to mometasone furoate or any inactive ingredient.
  • Individuals with recent nasal trauma, surgery, or septal ulcers (for nasal spray forms) until healing is complete.
  • The presence of primary cutaneous infections (for topical forms).

Age-Specific Eligibility and Restrictions

Dosage Form Minimum Approved Age Restriction
Topical Cream/Ointment 2 years and older Not recommended for ages under 2 years.
Nasal Spray (Rhinitis) 3 years and older Use not established for ages under 3 years.
Nasal Spray (Nasal Polyps) 18 years and older Not approved for ages under 18 years.

Conditional Use Populations

Use requires caution or risk assessment in several populations as safety profiles may be limited or risks are elevated, particularly for systemic absorption.

  • Pregnancy and Lactation: Use should occur only if the potential benefit justifies the risk, as data are limited. Infants of mothers who received the drug may require monitoring.
  • Organ Function: Caution is warranted in patients with severe hepatic or renal impairment as use is not fully established or may increase the risk of systemic effects like HPA axis suppression.
  • Active Infections: Use is generally not recommended or requires extreme caution in patients with active systemic infections, such as tuberculosis or untreated fungal, bacterial, or viral infections, due to the immunosuppressive nature of the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for MomeGalen (Mometasone Furoate) is structured around two principal types of interactions: those that alter the drug's concentration in the body and those that produce additive effects.

Type of Interaction Interacting Substances (Official Classification) Regulatory Outcome/Restriction
Pharmacokinetic (PK) Strong CYP3A4 Inhibitors (e.g., ritonavir, cobicistat) Increased systemic exposure (higher concentration) of Mometasone Furoate.
Pharmacodynamic (PD) Other Corticosteroid-containing products Additive systemic effects (increased risk of overall corticosteroid toxicity).
Substance Interaction Alcohol or CNS Depressants Avoid concurrent use due to potential for additional impairment of CNS performance.

Co-administration with potent CYP3A4 inhibitors is documented to increase MomeGalen's systemic exposure because this enzyme is essential for the drug’s metabolism. Likewise, concurrent use with other corticosteroids must be considered, as this combination leads to cumulative systemic exposure. Official labeling also includes a specific caution for patients with Hepatic Impairment, noting that systemic effects may be amplified due to the potential for slower clearance. No mandatory timing or separation requirements are formally documented.

Mechanism of Action

Receptor Binding and Genomic Modulation

MomeGalen (Mometasone Furoate) is a synthetic corticosteroid that works by binding with high affinity to intracellular glucocorticoid receptors (GRs). This drug-receptor complex then undergoes activation and moves into the cell nucleus, initiating genomic modulation by acting as a transcription regulator, which engages mechanisms that influence signaling within targeted physiological processes.

Suppression of Inflammatory Cascades

Once in the nucleus, the complex engages in transrepression, interfering with pro-inflammatory transcription factors like NF-kappaB and AP-1. This action suppresses the synthesis of chemical mediators—such as prostaglandins, leukotrienes, and cytokines—that drive inflammatory responses. This modification of early molecular steps influences excessive signaling within key inflammatory pathways.

Modulation of Vascular and Cellular Activity

Beyond gene regulation, MomeGalen exerts a targeted effect on the mobility and function of immune cells (e.g., lymphocytes and eosinophils). It also reduces capillary permeability and causes local vasoconstriction. These physiological effects restrict the accumulation of inflammatory cells and fluid in the affected area, supporting modulation within targeted peripheral systems.

Dosage and Administration Information

Administration and Dosing Instructions

MomeGalen (mometasone furoate) is available for two primary routes of administration: Topical (Cream, Ointment, or Lotion) and Intranasal (Nasal Spray). The following instructions describe the standard application protocols for these forms.

Topical Use (Cream, Ointment, Lotion 0.1%)

Feature Official Dosing Guideline
Route of Administration For external use only on the skin (cutaneous). Avoid contact with eyes and mouth.
Standard Dosing Apply a thin film to the affected skin areas once daily.
Age-Group Rules Approved for patients geq 2 years of age. Use for children below age 2 is not recommended.
Special Conditions Do not use with occlusive dressings (e.g., bandages, wraps) unless directed by a physician. Do not use in the diaper area as diapers may constitute an occlusive dressing. Therapy should be discontinued when control is achieved; if no improvement is seen within two weeks, reassess the diagnosis.

Intranasal Use (Nasal Spray 50 mcg/spray)

Feature Official Dosing Guideline
Route of Administration For intranasal use only. Avoid spraying into the eyes or mouth.
Standard Dosing Allergic Rhinitis (Adults geq 12 yrs): 2 sprays (100 mcg) in each nostril once daily. Allergic Rhinitis (Children 2-11 yrs): 1 spray (50 mcg) in each nostril once daily.
Preparation The pump must be primed prior to initial use (e.g., 10 actuations) or reprimed if unused for more than 1 week (e.g., 2 actuations), until a fine spray appears.
Missed Dose Rule If a dose is missed, apply it as soon as remembered. If it is almost time for the next dose, skip the missed dose and continue the regular schedule. Do not double doses.

MomeGalen is used according to its specified route and dosing schedule to ensure proper local drug delivery (topical or intranasal). The application technique, including the requirement for only a thin film (topical) or priming the device (intranasal), establishes the critical procedural steps. These protocols define the application of the medicine, including age-specific rules and time-limited administration.

Recent Clinical Evidence

MomeGalen: Recent Clinical Evidence

This section outlines the key findings from clinical trials and studies concerning the use of MomeGalen (Mometasone Furoate). The information presented is strictly descriptive of the studies performed and does not constitute medical advice or therapeutic recommendation.

Core Efficacy Studies

Clinical evidence primarily explores Mometasone Furoate's application as a potent synthetic corticosteroid for inflammatory and allergic conditions, including allergic rhinitis (seasonal and perennial), asthma, and corticosteroid-responsive dermatoses (e.g., eczema, psoriasis).

  • Allergic Rhinitis: Multiple randomized controlled trials (RCTs) investigated Mometasone Furoate nasal spray versus placebo. The studies examined whether there were changes in nasal symptom scores, such as congestion, sneezing, and itching. Subsequent meta-analyses assessed the consistency of these observed effects across various adult and pediatric patient groups.
  • Dermatoses: Research on topical formulations (cream/ointment) explored changes in inflammatory markers and overall skin condition scores in patients with conditions like atopic dermatitis and psoriasis compared to non-active vehicles or other standard treatments.

Safety Profile and Risk Factors

The evaluation of MomeGalen also extended to its safety profile, which varies depending on the route of administration (topical, nasal, or inhaled).

Administration Route Commonly Observed Adverse Events (as reported in studies)
Nasal Spray Headache, viral upper respiratory infection, nosebleeds
Topical Burning sensation, itching, dryness at the application site
  • Contraindications/Risk Factors: Studies note that people with pre-existing conditions (e.g., active or quiescent tuberculous infections of the respiratory tract, untreated viral infections, severe liver impairment) may have a greater risk of experiencing adverse events or systemic effects. Topical use over large surface areas or for long durations may also increase the potential for systemic absorption.
  • Systemic Effects: Due to the drug's high lipophilicity and low systemic bioavailability when used topically or intranasally, the potential for systemic effects, such as suppression of the hypothalamic-pituitary-adrenal (HPA) axis, was assessed in long-term studies and found to be low or absent in most subjects.

Key Studies & References

  1. Label: MOMETASONE FUROATE cream (Topical FDA Label)
  2. Efficacy of Topical Mometasone Furoate 0.1% Cream in the Treatment of Atopic Dermatitis
  3. Comparative Efficacy of Tacrolimus and Mometasone Furoate in Topical Treatment for Atopic Dermatitis: A Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about MomeGalen (FAQ)

Q: How quickly should I expect to see an improvement in my allergy symptoms after starting the nasal spray?

According to official product information, studies have indicated that some patients may begin to see improvement in nasal allergy symptoms within 11 to 12 hours after the first dose. However, regulatory documentation advises that the maximum benefit and full symptom benefits were generally reported after 1 to 2 weeks of use in clinical studies.

Q: What is the difference between MomeGalen Cream and MomeGalen Ointment?

Both the Cream and the Ointment formulations contain the same strength of the active ingredient, Mometasone Furoate 0.1%. The main difference lies in the base (or vehicle) used. Official documents indicate that the vehicle can affect how the medicine is absorbed through the skin, which determines factors such as the skin-penetrating capacity of the medication.

Q: Can I take MomeGalen while I'm pregnant?

Official information from regulatory documents states that the use of MomeGalen during pregnancy should only occur if the potential benefit justifies the potential risks. Animal studies have indicated that corticosteroids may carry a risk. Infants born to mothers who received corticosteroids during pregnancy may require observation for conditions like hypoadrenalism, a temporary decrease in adrenal gland function.

Q: What should I do if my child accidentally swallows the MomeGalen cream?

Regulatory information states that if MomeGalen is swallowed, do not induce vomiting. Official product information advises rinsing the mouth thoroughly with water. Immediate medical attention should be sought, as is the case with accidental ingestion of any medication.

How should MomeGalen be stored and disposed of?

How to Store and Dispose of MomeGalen: Official Requirements

Storage and disposal requirements for MomeGalen (Mometasone Furoate) are strictly defined to maintain product stability and ensure environmental safety. The medication must be kept at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F), with an explicit instruction to not freeze the product.

Required Handling

Area Requirement
Container Keep in the original container, tightly closed.
Protection Keep out of the reach of children.
Stability Do not use past the expiration date on the label.

Disposal

Unused or expired MomeGalen should not be flushed down the toilet or disposed of in household trash. Due to its classification as potentially toxic to aquatic life, disposal must follow local pharmaceutical collection programs or specific government-regulated waste instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGermany

flagPortugal

Equivalent of MomeGalen found in:

A-Z Index: